Celberus (CLBT, Financial) has announced its forecast for the second quarter, estimating an adjusted EBITDA ranging from $26 million to $28 million. This projection reflects the company's ongoing efforts to maintain financial stability and optimize performance metrics. Investors are keeping a close watch on these developments as they analyze Celberus' potential for market resilience and growth within the current economic climate.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Cellebrite DI Ltd (CLBT, Financial) is $27.33 with a high estimate of $28.00 and a low estimate of $26.00. The average target implies an upside of 35.85% from the current price of $20.12. More detailed estimate data can be found on the Cellebrite DI Ltd (CLBT) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Cellebrite DI Ltd's (CLBT, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cellebrite DI Ltd (CLBT, Financial) in one year is $11.17, suggesting a downside of 44.48% from the current price of $20.12. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cellebrite DI Ltd (CLBT) Summary page.
